A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03755518

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:27:03.081131+00:00

Published At

2023-03-09T00:00:00+00:00

Record Updated At

2024-12-12

Results Posted At

2023-03-09

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2024-12-12"

protocolSection.identificationModule.nctId

"NCT03755518"

protocolSection.identificationModule.officialTitle

"A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2023-03-09"

Study condition terms

• Primary Myelofibrosis (protocolSection.conditionsModule.conditions)
• Post-Polycythemia Vera Myelofibrosis (protocolSection.conditionsModule.conditions)
• Myelofibrosis (protocolSection.conditionsModule.conditions)
• Post-essential Thrombocythemia Myelofibrosis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.